BOT — Botanix Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- AU$317.16m
- AU$298.85m
- AU$0.17m
2019 June 30th | C2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.195 | 0.171 | 0.104 | 0.037 | 0.169 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 21.8 | 24.2 | 10.3 | 15.9 | 12.9 |
Operating Profit | -21.7 | -24.1 | -10.2 | -15.9 | -12.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -17 | -16.7 | -3.33 | -13.2 | -9.15 |
Provision for Income Taxes | |||||
Net Income After Taxes | -17 | -16.7 | -3.33 | -13.2 | -9.15 |
Net Income Before Extraordinary Items | |||||
Net Income | -17 | -16.7 | -3.33 | -13.2 | -9.15 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -17 | -16.7 | -3.33 | -13.2 | -9.15 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.022 | -0.018 | -0.003 | -0.014 | -0.008 |